Immuneering Corp (IMRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $240.27M
Last updated: Nov 17, 2026 at 4:38 PM ET
Immuneering Corp (IMRX) Statistics
Immuneering (IMRX) has a market cap of $240.27M and an enterprise value of $198.95M. Its share count is up 79.79% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 17.20% below the market cap, as cash exceeds debt.
| Market Cap | $240.27M |
|---|---|
| Enterprise Value | $198.95M |
| Latest price (Nov 17, 2026) | $3.46 |
Key Dates
| Last Earnings Date | Oct 29, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
| P/B Ratio | 1.2x |
|---|---|
| P/TBV Ratio | 1.2x |
Price Statistics
The stock is down 45.51% over 52 weeks and trades 12.18% below its 50-day average.
| Beta (1Y) | 1.37 |
|---|---|
| 52-Week Change | -45.51% |
| 1-Month Change | -5.46% |
| 3-Month Change | -35.08% |
| 6-Month Change | -29.24% |
| 5-Year Change | -86.18% |
| Total Return (1Y) | -45.51% |
| Total Return (3Y CAGR) | -14.83% |
| Total Return (5Y CAGR) | -33.26% |
| Return vs SPY (1Y) | -63.17% |
| Max Drawdown (1Y) | -59.54% |
| Max Drawdown (3Y) | -87.80% |
| Sharpe Ratio (1Y) | -0.82 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $3.94 |
| 200-Day Average | $4.73 |
| 52-Week Range | $3.35 to $8.48 |
| RSI (14 Days) | 41.3 |
| Average Volume (20 Days) | 794.96K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 19.47x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 19.47x |
|---|---|
| Quick Ratio | 19.47x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -30.03% over the last 12 months, against a 5-year average of -59.93%.
| Return on Equity (ROE) | -30.03% |
|---|---|
| Return on Assets (ROA) | -28.35% |
| ROE (5Y Average) | -59.93% |
| ROA (5Y Average) | -50.69% |
| ROIC (5Y Average) | -21.47% |
Scores
IMRX has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$612.73K |
| Operating Income | -$63.47M |
| Pretax Income | -$58.10M |
| Net Income | -$57.28M |
| Reported EPS (TTM) | -$1.03 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 94.40% of the $202.06M in total assets.
| Cash and Equivalents | $41.32M |
|---|---|
| Total Debt | $0 |
| Net Cash | $41.32M |
| Net Cash Per Share | $0.64 |
| Working Capital | $149.87M |
| Shareholder Equity | $190.74M |
| Book Value Per Share | $2.95 |
| Tangible Book Value | $183.74M |
| Tangible Book Per Share | $2.84 |
| Total Assets | $202.06M |
| Total Liabilities | $11.32M |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $238.46K of capital spending, operating cash flow left -$56.99M of free cash flow.
| Operating Cash Flow | -$56.75M |
|---|---|
| Capital Expenditures | $238.46K |
| Free Cash Flow | -$56.99M |
| FCF Per Share | -$0.88 |
| Depreciation and Amortization | $1.45M |
Trailing 12 months through Jun 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +26.66% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +29.78% |
Dividends and Yields
IMRX does not pay a dividend. Its free cash flow yield is -25.46%.
| FCF Yield | -25.46% |
|---|---|
| Buyback Yield | -94.99% |
| Shareholder Yield | -94.99% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About IMRX
What is IMRX's market cap?
Immuneering has a market cap of $240.27M. Its enterprise value, which adds debt and subtracts cash, is $198.95M.
How many shares of IMRX are outstanding?
Immuneering has 64.70M shares outstanding. The count is up 79.79% from a year earlier.
Does IMRX pay a dividend?
No. Immuneering does not pay a dividend.
How much debt does IMRX have?
Immuneering has $0 of total debt and $41.32M of cash and equivalents, a net cash position of $41.32M.
IMRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors